{
  "symbol": "ZNTL",
  "company_name": "Zentalis Pharmaceuticals Inc",
  "ir_website": "https://ir.zentalis.com/",
  "structured_data": [
    {
      "section_name": "News & Events",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://ir.zentalis.com/news-events/press-releases",
          "content": "[Skip to content](#lfg-main-content)\n\n[![Zentalis logo](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/zentalis-primary-logo.png)](https://zentalis.com/)\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/search-icon.svg) ![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/search-x.svg)\n\n[ ![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/Twitter-icon.svg) ](https://twitter.com/ZentalisP \"Twitter\") [ ![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/Linkedin-icon.svg) ](https://www.linkedin.com/company/zentalis-pharmaceuticals \"Linkedin\")\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)\n\nInvestors & Media\n\n# Press Releases\n\nInvestor Relations Menu\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)\n\n[ Investor Home](/investor-relations \"Investor Home\")\n\nNews & Events\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)\n\n[ Press Releases](/news-events/press-releases \"Press Releases\") [ Events & Presentations](/news-events/events-presentations \"Events & Presentations\")\n\nStock Information\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)\n\n[ Stock Quote & Chart](/stock-information/stock-quote-chart \"Stock Quote & Chart\") [ Historic Price Lookup](/stock-information/historic-price-lookup \"Historic Price Lookup\") [ Investment Calculator](/stock-information/investment-calculator \"Investment Calculator\") [ Analyst Coverage](/stock-information/analyst-coverage \"Analyst Coverage\")\n\nFinancials & Filings\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)\n\n[ SEC Filings](/financials-filings/sec-filings \"SEC Filings\")\n\nCorporate Governance\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)\n\n[ Documents & Charters](/corporate-governance/documents-charters \"Documents & Charters\") [ Management Team](http://zentalis.com/about/company/#management \"Management Team\") [ Board of Directors](http://zentalis.com/about/company/#board-of-directors \"Board of Directors\") [ Scientific Advisory Board](https://zentalis.com/about/company/#scientific-advisory-board \"Scientific Advisory Board\") [ Committee Composition](/corporate-governance/committee-composition \"Committee Composition\")\n\nInvestor Resources\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)\n\n[ Investor FAQs](/investor-resources/investor-faqs \"Investor FAQs\") [ Investor Contact](/investor-resources/investor-contact \"Investor Contact\") [ Email Alerts](/investor-resources/email-alerts \"Email Alerts\")\n\n**Contact**\n\nElizabeth Pingpank Hickin Vice President, Investor Relations ehickin@zentalis.com\n\nYear All202420232022202120202019\n\n2024\n\nDec 02, 2024 \n\n[Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/news-releases/news-release-details/zentalis-pharmaceuticals-announces-inducement-grants-under-17)\n\nNov 13, 2024 \n\n[Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib](/news-releases/news-release-details/zentalis-pharmaceuticals-announces-executive-leadership-changes)\n\nNov 01, 2024 \n\n[Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/news-releases/news-release-details/zentalis-pharmaceuticals-announces-inducement-grants-under-16)\n\nSep 16, 2024 \n\n[Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies](/news-releases/news-release-details/zentalis-pharmaceuticals-announces-fda-has-lifted-partial)\n\nSep 09, 2024 \n\n[Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024](/news-releases/news-release-details/zentalis-pharmaceuticals-present-preclinical-azenosertib-data)\n\nSep 03, 2024 \n\n[Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/news-releases/news-release-details/zentalis-pharmaceuticals-announces-inducement-grants-under-15)\n\nAug 09, 2024 \n\n[Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress](/news-releases/news-release-details/zentalis-pharmaceuticals-reports-second-quarter-2024-financial)\n\nAug 01, 2024 \n\n[Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/news-releases/news-release-details/zentalis-pharmaceuticals-announces-inducement-grants-under-14)\n\nJul 01, 2024 \n\n[Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/news-releases/news-release-details/zentalis-pharmaceuticals-announces-inducement-grants-under-13)\n\nJun 18, 2024 \n\n[Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program](/news-releases/news-release-details/zentalis-pharmaceuticals-provides-update-azenosertib-clinical)\n\nDisplaying 1 - 10 of 27 \n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/zentalis-primary-logo.png)\n\nScience Center\n\n10275 Science Center Drive Suite 200 San Diego, CA 92121\n\nCopyright Â© 2024 Zentalis Pharmaceuticals.All Rights Reserved.\n\nAbout Us\n\n[ Our Company](https://www.zentalis.com/about/company \"Our Company\") [ Management Team](https://zentalis.com/about/company/#management \"Management Team\") [ Board of Directors](https://zentalis.com/about/company/#board-of-directors \"Board of Directors\") [ Scientific Advisory Board](https://zentalis.com/about/company/#scientific-advisory-board \"Scientific Advisory Board\") [ Partners & Collaborations](https://zentalis.com/about/company/#partners-collaborations \"Partners & Collaborations\") [ Contact](https://zentalis.com/about/contact/ \"Contact\")\n\nOur Pipeline\n\n[ Overview](https://zentalis.com/our-pipeline/pipeline/ \"Pipeline\") [ Azenosertib](https://zentalis.com/pipeline/pipeline#azenosertib \"Azenosertib\") [ Clinical Trials](https://zentalis.com/our-pipeline/clinical-trials/ \"Clinical Trials\")\n\nOur Approach\n\n[ Integrated Discovery Engine](https://zentalis.com/our-approach/integrated-discovery-engine/ \"Integrated Discovery Engine\") [ Supporting Publications](https://zentalis.com/our-approach/publications/ \"Supporting Publications\")\n\nInvestors & Media\n\n[ News & Events](/news-events/press-releases \"News & Events\") [ Stock Information](/stock-information/stock-quote-chart \"Stock Information\") [ Financials & Filings](/financials-filings/sec-filings \"Financials & Filings\") [ Corporate Governance](/corporate-governance/documents-charters \"Corporate Governance\") [ Investor Resources](/investor-resources/investor-faqs \"Investor Resources\")\n\n[ ![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/Twitter-icon.svg) ](https://twitter.com/ZentalisP \"Twitter\") [ ![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/Linkedin-icon.svg) ](https://www.linkedin.com/company/zentalis-pharmaceuticals \"Linkedin\")\n\n[Privacy Policy](https://zentalis.com/privacy-policy/ \"Privacy Policy\") [Terms of Use](https://zentalis.com/terms-of-use/ \"Terms of Use\") [Expanded Access Policy](https://zentalis.com/expanded-access-policy/ \"Expanded Access Policy\") [Site Map](https://zentalis.com/site-map/ \"Site Map\") [Careers](https://www.zentalis.com/careers/why-zentalis \"Careers\")\n"
        },
        {
          "title": "Events & Presentations",
          "url": "https://ir.zentalis.com/news-events/events-presentations",
          "content": "[Skip to content](#lfg-main-content)\n\n[![Zentalis logo](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/zentalis-primary-logo.png)](https://zentalis.com/)\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/search-icon.svg) ![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/search-x.svg)\n\n[ ![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/Twitter-icon.svg) ](https://twitter.com/ZentalisP \"Twitter\") [ ![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/Linkedin-icon.svg) ](https://www.linkedin.com/company/zentalis-pharmaceuticals \"Linkedin\")\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)\n\nInvestors & Media\n\n# Events & Presentations\n\nInvestor Relations Menu\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)\n\n[ Investor Home](/investor-relations \"Investor Home\")\n\nNews & Events\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)\n\n[ Press Releases](/news-events/press-releases \"Press Releases\") [ Events & Presentations](/news-events/events-presentations \"Events & Presentations\")\n\nStock Information\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)\n\n[ Stock Quote & Chart](/stock-information/stock-quote-chart \"Stock Quote & Chart\") [ Historic Price Lookup](/stock-information/historic-price-lookup \"Historic Price Lookup\") [ Investment Calculator](/stock-information/investment-calculator \"Investment Calculator\") [ Analyst Coverage](/stock-information/analyst-coverage \"Analyst Coverage\")\n\nFinancials & Filings\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)\n\n[ SEC Filings](/financials-filings/sec-filings \"SEC Filings\")\n\nCorporate Governance\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)\n\n[ Documents & Charters](/corporate-governance/documents-charters \"Documents & Charters\") [ Management Team](http://zentalis.com/about/company/#management \"Management Team\") [ Board of Directors](http://zentalis.com/about/company/#board-of-directors \"Board of Directors\") [ Scientific Advisory Board](https://zentalis.com/about/company/#scientific-advisory-board \"Scientific Advisory Board\") [ Committee Composition](/corporate-governance/committee-composition \"Committee Composition\")\n\nInvestor Resources\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)\n\n[ Investor FAQs](/investor-resources/investor-faqs \"Investor FAQs\") [ Investor Contact](/investor-resources/investor-contact \"Investor Contact\") [ Email Alerts](/investor-resources/email-alerts \"Email Alerts\")\n\n**Contact**\n\nElizabeth Pingpank Hickin Vice President, Investor Relations ehickin@zentalis.com\n\n## Corporate Presentation\n\nMore information is coming soon.\n\n## Upcoming Events\n\nThere are no upcoming events available at this time. \n\n## Past Events\n\nJun 18, 2024 8:00 AM EDT\n\nZentalis Pharmaceuticals Investor Call\n\n[Click Here for Webcast](https://edge.media-server.com/mmc/p/y2wz6vv6)\n\nSupporting Materials\n\n[Investor Call Deck](/static-files/42d2a2b0-0abf-422d-965d-cc6d596ccef2 \"Zentalis Corporate Update June 2024.pdf\") 343.8 KB\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/zentalis-primary-logo.png)\n\nScience Center\n\n10275 Science Center Drive Suite 200 San Diego, CA 92121\n\nCopyright Â© 2024 Zentalis Pharmaceuticals.All Rights Reserved.\n\nAbout Us\n\n[ Our Company](https://www.zentalis.com/about/company \"Our Company\") [ Management Team](https://zentalis.com/about/company/#management \"Management Team\") [ Board of Directors](https://zentalis.com/about/company/#board-of-directors \"Board of Directors\") [ Scientific Advisory Board](https://zentalis.com/about/company/#scientific-advisory-board \"Scientific Advisory Board\") [ Partners & Collaborations](https://zentalis.com/about/company/#partners-collaborations \"Partners & Collaborations\") [ Contact](https://zentalis.com/about/contact/ \"Contact\")\n\nOur Pipeline\n\n[ Overview](https://zentalis.com/our-pipeline/pipeline/ \"Pipeline\") [ Azenosertib](https://zentalis.com/pipeline/pipeline#azenosertib \"Azenosertib\") [ Clinical Trials](https://zentalis.com/our-pipeline/clinical-trials/ \"Clinical Trials\")\n\nOur Approach\n\n[ Integrated Discovery Engine](https://zentalis.com/our-approach/integrated-discovery-engine/ \"Integrated Discovery Engine\") [ Supporting Publications](https://zentalis.com/our-approach/publications/ \"Supporting Publications\")\n\nInvestors & Media\n\n[ News & Events](/news-events/press-releases \"News & Events\") [ Stock Information](/stock-information/stock-quote-chart \"Stock Information\") [ Financials & Filings](/financials-filings/sec-filings \"Financials & Filings\") [ Corporate Governance](/corporate-governance/documents-charters \"Corporate Governance\") [ Investor Resources](/investor-resources/investor-faqs \"Investor Resources\")\n\n[ ![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/Twitter-icon.svg) ](https://twitter.com/ZentalisP \"Twitter\") [ ![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/Linkedin-icon.svg) ](https://www.linkedin.com/company/zentalis-pharmaceuticals \"Linkedin\")\n\n[Privacy Policy](https://zentalis.com/privacy-policy/ \"Privacy Policy\") [Terms of Use](https://zentalis.com/terms-of-use/ \"Terms of Use\") [Expanded Access Policy](https://zentalis.com/expanded-access-policy/ \"Expanded Access Policy\") [Site Map](https://zentalis.com/site-map/ \"Site Map\") [Careers](https://www.zentalis.com/careers/why-zentalis \"Careers\")\n"
        }
      ]
    },
    {
      "section_name": "Financials & Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://ir.zentalis.com/financials-filings/sec-filings",
          "content": "[Skip to content](#lfg-main-content)\n\n[![Zentalis logo](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/zentalis-primary-logo.png)](https://zentalis.com/)\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/search-icon.svg) ![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/search-x.svg)\n\n[ ![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/Twitter-icon.svg) ](https://twitter.com/ZentalisP \"Twitter\") [ ![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/Linkedin-icon.svg) ](https://www.linkedin.com/company/zentalis-pharmaceuticals \"Linkedin\")\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)\n\nInvestors & Media\n\n# SEC Filings\n\nInvestor Relations Menu\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/hambuger-line.svg)\n\n[ Investor Home](/investor-relations \"Investor Home\")\n\nNews & Events\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)\n\n[ Press Releases](/news-events/press-releases \"Press Releases\") [ Events & Presentations](/news-events/events-presentations \"Events & Presentations\")\n\nStock Information\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)\n\n[ Stock Quote & Chart](/stock-information/stock-quote-chart \"Stock Quote & Chart\") [ Historic Price Lookup](/stock-information/historic-price-lookup \"Historic Price Lookup\") [ Investment Calculator](/stock-information/investment-calculator \"Investment Calculator\") [ Analyst Coverage](/stock-information/analyst-coverage \"Analyst Coverage\")\n\nFinancials & Filings\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)\n\n[ SEC Filings](/financials-filings/sec-filings \"SEC Filings\")\n\nCorporate Governance\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)\n\n[ Documents & Charters](/corporate-governance/documents-charters \"Documents & Charters\") [ Management Team](http://zentalis.com/about/company/#management \"Management Team\") [ Board of Directors](http://zentalis.com/about/company/#board-of-directors \"Board of Directors\") [ Scientific Advisory Board](https://zentalis.com/about/company/#scientific-advisory-board \"Scientific Advisory Board\") [ Committee Composition](/corporate-governance/committee-composition \"Committee Composition\")\n\nInvestor Resources\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/accordion-icon.svg)\n\n[ Investor FAQs](/investor-resources/investor-faqs \"Investor FAQs\") [ Investor Contact](/investor-resources/investor-contact \"Investor Contact\") [ Email Alerts](/investor-resources/email-alerts \"Email Alerts\")\n\n**Contact**\n\nElizabeth Pingpank Hickin Vice President, Investor Relations ehickin@zentalis.com\n\nGroup - Any -3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\n- Any -\n\nFiling year All20242023202220212020201920182017\n\nAll\n\nItems per page 102550\n\n10\n\n[Filing Date](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"Sort By Filing Date\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"Sort By Form\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"Sort By Description\") | View  \n---|---|---|---  \nNov 14, 2024 |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001104659-24-118978) |  An amendment to the SC 13G filing |  [0001104659-24-118978.pdf](/static-files/9d7e6302-7996-43a5-88ca-6cc250944af3) [0001104659-24-118978.rtf](/static-files/b88b41ae-c2fc-4e52-9073-9c54b59d8afe) [View HTML](/node/10191/html)  \nNov 13, 2024 |  [8-K](/sec-filings/sec-filing/8-k/0001725160-24-000177) |  Report of unscheduled material events or corporate event |  [0001725160-24-000177.pdf](/static-files/6d17f424-f7c5-46ae-b140-91d7d02c38bf) [0001725160-24-000177.rtf](/static-files/fae8eed9-31c3-4a6e-8c19-e8dc128dbc91) [0001725160-24-000177.xls](/static-files/5d431012-cbfb-4e83-8dad-748ff145bf6a) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001725160-24-000177) [View HTML](/node/10166/html)  \nNov 13, 2024 |  [3](/sec-filings/sec-filing/3/0001725160-24-000183) |  Initial filing by director officer or owner of more than ten percent |  [0001725160-24-000183.pdf](/static-files/6fb974f0-0b3e-4339-a140-dc4dc01b3d00) [0001725160-24-000183.rtf](/static-files/21a36ee0-4dee-4358-835f-3f218b152288) [0001725160-24-000183.xls](/static-files/06daf44a-b1d4-4144-8a5c-98be55a7fd4d) [View HTML](/node/10171/html)  \nNov 13, 2024 |  [3](/sec-filings/sec-filing/3/0001725160-24-000185) |  Initial filing by director officer or owner of more than ten percent |  [0001725160-24-000185.pdf](/static-files/033fb458-60f3-4d8c-b245-088f5d413cc0) [0001725160-24-000185.rtf](/static-files/47593531-2735-49d5-9464-30273b3318f5) [0001725160-24-000185.xls](/static-files/d44e0c48-fa02-4631-ae2d-f831fb7f24d3) [View HTML](/node/10176/html)  \nNov 13, 2024 |  [3](/sec-filings/sec-filing/3/0001725160-24-000184) |  Initial filing by director officer or owner of more than ten percent |  [0001725160-24-000184.pdf](/static-files/bbeeeb42-6a47-4e55-aec2-441550ed20db) [0001725160-24-000184.rtf](/static-files/6dd3c443-00d7-47e9-b870-39bd5e574693) [0001725160-24-000184.xls](/static-files/94fec172-97cd-43da-b11f-2665825fb3fa) [View HTML](/node/10181/html)  \nNov 13, 2024 |  [4](/sec-filings/sec-filing/4/0001725160-24-000186) |  Statement of changes in beneficial ownership of securities |  [0001725160-24-000186.pdf](/static-files/c1f46dab-1bff-4f36-853a-27d52bce5bab) [0001725160-24-000186.rtf](/static-files/e8513591-4922-4701-8820-ba0fca279061) [0001725160-24-000186.xls](/static-files/e0e537f9-d891-45f8-a770-e879a173ed2e) [View HTML](/node/10186/html)  \nNov 12, 2024 |  [10-Q](/sec-filings/sec-filing/10-q/0001725160-24-000173) |  Quarterly report which provides a continuing view of a company's financial position |  [0001725160-24-000173.pdf](/static-files/73c3f012-45bb-465e-8e9b-11dce248acf5) [0001725160-24-000173.rtf](/static-files/178c3817-627f-4caf-97dd-a061062268ec) [0001725160-24-000173.xls](/static-files/128d82ec-f41c-4c6d-90ca-2d0b48114c5d) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0001725160-24-000173) [View HTML](/node/10146/html)  \nNov 12, 2024 |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0000932471-24-001300) |  An amendment to the SC 13G filing |  [0000932471-24-001300.pdf](/static-files/70aef873-6b04-4767-bbfa-13fdfca6ca01) [0000932471-24-001300.rtf](/static-files/d244428a-85af-46e7-b984-8cc18f07595e) [View HTML](/node/10151/html)  \nNov 06, 2024 |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001580642-24-006742) |  An amendment to the SC 13G filing |  [0001580642-24-006742.pdf](/static-files/48855241-d11c-43a3-8691-a1f23db0efb1) [0001580642-24-006742.rtf](/static-files/716b3c03-c7c2-443c-a660-f957cb135386) [0001580642-24-006742.xls](/static-files/1ff9d8c5-c3a8-436e-b5db-4bdcbf23ce27) [View HTML](/node/10141/html)  \nNov 04, 2024 |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0000932471-24-000785) |  An amendment to the SC 13G filing |  [0000932471-24-000785.pdf](/static-files/f965ffe0-5092-4dbc-955d-d3707c2c6263) [0000932471-24-000785.rtf](/static-files/b093f64e-8414-47cd-b5af-6b2d6391a0fd) [View HTML](/node/10136/html)  \n  \nDisplaying 1 - 10 of 429 results\n\nData provided by [Kaleidoscope](https://www.kscope.io).\n\n![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/zentalis-primary-logo.png)\n\nScience Center\n\n10275 Science Center Drive Suite 200 San Diego, CA 92121\n\nCopyright Â© 2024 Zentalis Pharmaceuticals.All Rights Reserved.\n\nAbout Us\n\n[ Our Company](https://www.zentalis.com/about/company \"Our Company\") [ Management Team](https://zentalis.com/about/company/#management \"Management Team\") [ Board of Directors](https://zentalis.com/about/company/#board-of-directors \"Board of Directors\") [ Scientific Advisory Board](https://zentalis.com/about/company/#scientific-advisory-board \"Scientific Advisory Board\") [ Partners & Collaborations](https://zentalis.com/about/company/#partners-collaborations \"Partners & Collaborations\") [ Contact](https://zentalis.com/about/contact/ \"Contact\")\n\nOur Pipeline\n\n[ Overview](https://zentalis.com/our-pipeline/pipeline/ \"Pipeline\") [ Azenosertib](https://zentalis.com/pipeline/pipeline#azenosertib \"Azenosertib\") [ Clinical Trials](https://zentalis.com/our-pipeline/clinical-trials/ \"Clinical Trials\")\n\nOur Approach\n\n[ Integrated Discovery Engine](https://zentalis.com/our-approach/integrated-discovery-engine/ \"Integrated Discovery Engine\") [ Supporting Publications](https://zentalis.com/our-approach/publications/ \"Supporting Publications\")\n\nInvestors & Media\n\n[ News & Events](/news-events/press-releases \"News & Events\") [ Stock Information](/stock-information/stock-quote-chart \"Stock Information\") [ Financials & Filings](/financials-filings/sec-filings \"Financials & Filings\") [ Corporate Governance](/corporate-governance/documents-charters \"Corporate Governance\") [ Investor Resources](/investor-resources/investor-faqs \"Investor Resources\")\n\n[ ![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/Twitter-icon.svg) ](https://twitter.com/ZentalisP \"Twitter\") [ ![](/sites/g/files/knoqqb84091/themes/site/client_site/dist/images/Linkedin-icon.svg) ](https://www.linkedin.com/company/zentalis-pharmaceuticals \"Linkedin\")\n\n[Privacy Policy](https://zentalis.com/privacy-policy/ \"Privacy Policy\") [Terms of Use](https://zentalis.com/terms-of-use/ \"Terms of Use\") [Expanded Access Policy](https://zentalis.com/expanded-access-policy/ \"Expanded Access Policy\") [Site Map](https://zentalis.com/site-map/ \"Site Map\") [Careers](https://www.zentalis.com/careers/why-zentalis \"Careers\")\n"
        }
      ]
    }
  ]
}